Status:

COMPLETED

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

Lead Sponsor:

Nabi Biopharmaceuticals

Conditions:

Hyperphosphatemia

Kidney Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.

Detailed Description

In patients with impaired kidney function, dietary phosphorus can not be completely excreted, which leads to elevated levels of serum phosphorus. Elevated serum phosphorus leads to increased levels of...

Eligibility Criteria

Inclusion

  • Non-dialyzed male or female patients with CKD, with a GFR of less than 30mL/min/1.73m² who have elevated serum phosphorus or who develop elevated serum phosphorus following washout from phosphorus-binding therapy.
  • Patients must have written informed consent
  • Negative serum pregnancy test if appropriate
  • Expected to be able to comply with protocol procedures and schedule

Exclusion

  • Unstable angina pectoris
  • Severe congestive heart failure
  • Severe liver dysfunction
  • Severe malnutrition
  • Severe hyperparathyroidism
  • AIDS (HIV positive subjects without AIDS are not excluded)
  • Active malignancy for which the subject is receiving chemotherapy or radiation
  • Subject unlikely to complete the study
  • History of obstructed bowels or hypersensitivity to any of the study medications or their components
  • History of swallowing disorders such as dysphagia (that would prevent the subject from taking the study drug) severe gastrointestinal motility disorders, or major GI tract surgery
  • Participation in an investigational drug or device trial within 30 days of randomization
  • Subjects on Vitamin D therapy
  • Subjects with acute symptoms, in the last month, or current radiographic evidence of kidney stones
  • Subjects who have undergone renal transplant or receiving dialysis
  • Or any condition with makes patient participation not in the patients best interest

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2006

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT00211978

Start Date

May 1 2005

End Date

October 1 2006

Last Update

January 8 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas Health Sciences Center

San Antonio, Texas, United States, 78229-3900